Rational design of novel potential p38α MAPK inhibitors with drug-like properties using pharmacophore and similarity-based virtual screening procedures

Current Bioactive Compounds

Volumn 9, Issue 1, 2013, Pages 3-13

  Pinsetta, F R ^a   Taft, C A ^b   Silva, C H T P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO BRASILEIRO DE PESQUISAS FÍSICAS   (Brazil)

Author keywords

Inhibitors; p38a MAPK; Pharmacophore; Rational drug design

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; COMPUTER PROGRAM; CRYSTALLOGRAPHY; DATA BASE; DRUG ACTIVITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME INHIBITION; IC 50; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; TOXICITY TESTING; VIRTUAL REALITY;

EID: 84876845936     PISSN: 15734072     EISSN: 18756646     Source Type: Journal    
DOI: 10.2174/1573407211309010002     Document Type: Article

References (37)

1. Zhang, Y.Y.; Mei, Z.Q.; Wu, J.W.; Wang, Z.X. Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphorylation states. J. Biol. Chem., 2008, 283, 26591-26601.
2. Chico, L.K.; Van Eldik, L.J.; Watterson, D.M. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov., 2009, 8, 892-909.
3. Yasuda, S.; Sugiura, H.; Tanaka, H.; Takigami, S.; Yamagata, K. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent. Nerv. Syst. Agents Med. Chem., 2011,11, 45-59.
4. Sheng, J.G.; Jones, R.A.; Zhou, X.Q.; McGinness, J.M.; Van Eldik, L.J.; Mrak, R.E.; Griffin, W.S. Interleukin-1 promotion of MAPKp38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem. Int., 2001, 39, 341-348.
5. Dalrymple, S.A. p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. J. Mol. Neurosci., 2002. 19, 295-299.
6. Munoz, L.; Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology, 2010, 58(3), 561-568.
7. Culbert, A.A.; Skaper, S.D.; Howlett, D.R.; Evans, N.A.; Facci, L.; Soden, P.E.; Seymour, Z.M.; Guillot, F.; Gaestel, M.; Richardson, J.C. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem., 2006, 281, 23658-23667.
8. De Strooper, B.; Konig, G. An inflammatory drug prospect. Nature, 2001, 414, 159-160.
9. Sastre, M.; Klockgether, T.; Heneka, M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci., 2006, 24, 167-176.
10. Johnson, G.V.; Bailey, C.D. The p38 MAP kinase signaling pathway in Alzheimer's disease. Exp. Neurol., 2003, 183, 263-268.
11. Lee, M.R.; Dominguez, C. MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein. Curr. Med. Chem., 2005, 12, 2979-2994.
12. Simard, J.R.; Grütter, C.; Pawar, V.; Aust, B.; Wolf, A.; Rabiller, M.; Wulfert, S.; Robubi, A.; Klüter, S.; Ottmann, C.; Rauh, D. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. J. Am. Chem. Soc., 2009, 131, 18478-18488.
13. Lengauer, T. Bioinformatics: from genomes to drugs. Methods and principles in medicinal chemistry. Weinheim: Wiley-VHC Verlag, 2002, 1.
14. Silva, C.H.T.P.; Bernardes, L.S.C.; da Silva, V.B.; Zani, C.L.; Carvalho, I. Novel aryl beta-aminocarbonyl derivatives as inhibitors of Trypanosoma cruzi trypanothione reductase: binding mode revised by docking and GRIND2-based 3D-QSAR procedures. J. Biomol. Struct. Dyn., 2012, 29, 103-117.
15. Mancini, D.T.; Matos, K.S.; Cunha, E.F.F.; Assis, T.M.; Guimarães, A.P.; França, T.C.C.; Ramalho, T.C. Molecular modeling studies on nucleoside hydrolase from the biological warfare agent Brucella suis. J. Biomol. Struct. Dyn., 2012, 30, 125-136.
16. Hert, J.; Willett, P.; Wilton, D.J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures. J. Chem. Inf. Comput. Sci., 2004, 44, 1177-1185.
17. Zhong, H.B.; Phillip, J. GALAHAD pharmacophore modeling for drug discovery. J. Am. Chem. Soc., 2007, 129, 5780-5780.
18. Chen, X.; Lin, Y.; Liu, M.; Gilson, M.K. The Binding Database: data management and interface design. Bioinformatics, 2002, 18 130-139.
19. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R.N.; Gilson, M.K. BindingDB: a web-accessible database of experimentally determined proteinligand binding affinities. Nucleic Acids Res., 2007, 35(Database issue): p. D198-201.
20. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Research, 2000, 28, 235-242.
21. Guex, N.; Peitsch, M.C. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis, 1997, 18, 2714-2723.
22. Laurie, A.T.; Jackson, R.M. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics (Oxford, England), 2005, 21, 1908-1916.
23. Loper, J.E., Kobayashi, D.Y.; Paulsen, I.T. The Genomic Sequence of Pseudomonas fluorescens Pf-5: Insights Into Biological Control. Phytopathology, 2007, 97, 233-238.
24. Allen, F.H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta. Crystallogr. B., 2002, 58, 380-388.
25. Irwin, J.J.; Shoichet, B.K. ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2005, 45, 177-82.
26. Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. ZINC: A Free Tool to Discover Chemistry for Biology. Journal of Chemical Information and Modeling, 2012, 52, 1757-1768
27. OMEGA, Versão 2.0, Openeyes Scientific Software: Santa Fe, NM, 2006.
28. Koes, D.R.; Camacho, C.J. ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res., 2012, 40(Web Server issue): p. W409-14.
29. Schneidman-Duhovny, D.; et al., PharmaGist: a webserver for ligand-based pharmacophore detection. Nucleic Acids Res., 2008, 36(Web Server issue): p. W223-8.
30. Kirchmair, J.; Wolber, G.; Laggner, C.; Langer, T. Comparative Performance Assessment of the Conformational Model Generators OMEGA and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations. Journal of Chemical Information and Modeling, 2006, 46, 1848-1861.
31. Liu, X.; Ouyang, S.; Yu, B.; Liu, Y.; Huang, K.; Gong, J.; Zheng, S.; Li, Z.; Li, H.; Jiang, H. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res., 2010, 38(Web Server issue): W609-14.
32. Benfenati, E.; Gini, G. Computational predictive programs (expert systems) in toxicology. Toxicology, 1997, 119(3), 213-225.
33. Mohan, C.G.; Gandhi, T.; Garg, D.; Shinde, R. Computer-Assisted Methods in Chemical Toxicity Prediction. Mini Reviews in Medicinal Chemistry, 2007, 5, 499-507.
34. Muster, W.; Breidenbach, A.; Fischer, H.; Kirchner, S.; Müller, L.; Pähler, A. Computational toxicology in drug development. Drug Discov. Today, 2008, 13, 303-310.
35. QikProp, version 3.4, Schrödinger, LLC, Schrödinger: New York, NY, 2011.
36. Mavel, S.; Thery, I.; Gueiffier, A. Synthesis of imidazo[2,1-a]phthalazines, potential inhibitors of p38 MAP kinase. Prediction of binding affinities of protein ligands. Arch. Pharm. (Weinheim), 2002, 335, 7-14.
37. Larkin, M.A.; Blackshields, G.; Brown, N.P.; Chenna, R.; McGettigan, P.A.; McWilliam, H.; Valentin, F.; Wallace, I.M.; Wilm, A.; Lopez, R.; Thompson, J.D.; Gibson, T.J.; Higgins, D.G. Clustal W and Clustal X version 2.0. Bioinformatics, 2007, 23, 2947-2948.